Evidence map›Paper›PMID 41549603›Full record

ArticlePediatric blood & cancer2026

Pathogenic Germline PALB2 and RAD50 Variants in Patients With Relapsed Ewing Sarcoma.

Molly Mack, A Carolina Tufino, Mohd Azrin Jamalruddin, Sreya Dey, Yinghong Pan, Elina Mukherjee, Jessica D Daley, Julia Meade, Mahmoud Aarabi, Lisa Maurer and 3 more

Abstract readCase Reports
In one paragraph

Article in Pediatric blood & cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Molly MackUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
A Carolina TufinoUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Mohd Azrin JamalruddinGraduate Group in Biochemistry and Molecular Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Sreya DeyUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Yinghong PanDepartment of Obstetrics and Gynecology, UPMC Magee-Women's Hospital, Pittsburgh, Pennsylvania, USA.
Elina MukherjeeUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Jessica D DaleyUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Julia MeadeUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Mahmoud AarabiDepartment of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Lisa MaurerUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
James CooperUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Kara A BernsteinDepartment of Biochemistry and Biophysics, Penn Center for Genome Integrity, Basser Center for BRCA, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Kelly M BaileyUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Funding

Research Training Program for Pediatric Subspecialty FellowsT32HD071834 · NICHD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TERENCE S. DERMODY · 2013 to 2026
$4.7M
Replication fork dynamics and repair by Rad51 paralogues after DNA alkylationR01ES030335 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Kara A Bernstein · 2019 to 2026
$2.9M
DNA Damage and Immunogenicity in Ewing SarcomaK08CA252178 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BAILEY, KELLY · 2021 to 2025
$765k
NCI NIH HHS 1K08CA252178NCI NIH HHS K08 CA252178NIH HHS ES031796NIH HHS R01 ES030335NIH HHS T32HD071834UPMC Children's Foundation
6 · The paper itself

Abstract

Approximately 10% of patients with Ewing sarcoma (EwS) have pathogenic germline variants. Here, we report two cases: first, a novel germline pathogenic variant in partner and localizer of BRCA2 (PALB2) in a patient with a late EwS relapse. Its impact on homologous recombination is demonstrated, and breast cancer risk is discussed. Second, we report a pathogenic germline variant in RAD50 in a patient with a rare prostate primary EwS and later concurrent relapsed EwS and therapy-related acute myeloid leukemia (tAML) with two rare KMT2A translocations. Understanding rare pathogenic germline variants and the impact on cancer behavior, response to treatment and treatment-associated toxicities is important for patients.

Indexed as

Bone NeoplasmsDNA-Binding ProteinsDNA Repair EnzymesFanconi Anemia Complementation Group N ProteinGerm-Line MutationNeoplasm Recurrence, LocalSarcoma, EwingAcid Anhydride HydrolasesChildFemaleHumansLeukemia, Myeloid, AcuteMaleAcid Anhydride HydrolasesDNA-Binding ProteinsDNA Repair EnzymesFanconi Anemia Complementation Group N ProteinPALB2 protein, humanRAD50 protein, humanbreast cancerEwing sarcomapartner and localizer of BRCA2 (PALB2)RAD50treatment‐related acute myeloid leukemia (tAML)

Identifiers

PMID41549603
PMCPMC13222620

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.